1.Explore the Optimal Resolvent of Medical Needs and Mental Health for Patients with Lung Cancer during Epidemic Novel Coronavirus Pneumonia.
Haiyan XU ; Ke YANG ; Guangjian YANG ; Lu YANG ; Yuling MI ; Xiaohong CUI ; Min YANG ; Dan WANG ; Yan WANG
Chinese Journal of Lung Cancer 2020;23(4):247-254
BACKGROUND:
With the rapid spread of novel coronavirus pneumonia (NCP) worldwide and the escalation of prevention and control efforts, the routine medical needs of patients have been restricted. The aims were to investigate medical needs of lung cancer patients and their mental health status during the epidemic periods, so as to provide rational recommendations for subsequent diagnosis and treatment.
METHODS:
The questionnaire was sent in the form of an electronic questionnaire at 7am on 4th, March, 2020, until 7am 6th, March, 2020, 368 questionnaires were recollected from 25 provinces (autonomous regions/municipalities) in 48 h.
RESULTS:
Of the 368 patients, 18 patients were excluded as they didn't receive anti-tumor treatment, and 350 patients were included in the final analysis. 229 cases were treated with oral targeted drugs, and 121 cases were treated with chemotherapy or immunotherapy. 41.3% of patients treated with intravenous chemotherapy or immunotherapy experienced treatment discontinuation, and the proportion of treatment discontinuation in chemotherapy or immunotherapy was higher than those treated with oral targeted drugs (21.0%). Whether oral targeted drugs or intravenous chemotherapy or immunotherapy, more than 60% of patients experienced delays in imaging examinations. Nearly one third of patients developed new symptoms or exacerbation of existing symptoms. 26.6%-28.9% of patients have changed their treatment plans through online consultation. During novel coronavirus pneumonia, 40%-75% of lung cancer patients have mental health problems, and more than 95% of patients support government's prevention and control measures.
CONCLUSIONS
During the emergence of NCP, the medical needs of patients with lung cancer have not been enough, especially those who discontinued chemotherapy or immunotherapy. When medical institution resumes work, priority should be given to them. At the same time, mental health problems of patients should be valued and resolved timely.
Adult
;
Aged
;
Antineoplastic Agents
;
therapeutic use
;
Betacoronavirus
;
physiology
;
China
;
epidemiology
;
Coronavirus Infections
;
epidemiology
;
virology
;
Female
;
Humans
;
Lung Neoplasms
;
drug therapy
;
psychology
;
Male
;
Middle Aged
;
Pandemics
;
Pneumonia
;
epidemiology
;
virology
;
Pneumonia, Viral
;
epidemiology
;
virology
;
Retrospective Studies
2.Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors.
Lu TIAN ; Wenjun LIU ; Lei SUN
Chinese Journal of Biotechnology 2020;36(4):605-611
Cyclophilin A (CypA) is a widely distributed and highly conserved protein in organisms. It has peptidyl-prolyl cis/trans isomerase activity and is a receptor for cyclosporin A (CsA). Coronaviruses are enveloped, single-stranded, positive-sense RNA viruses. Seven types of coronaviruses are currently known to infect humans, among which SARS-CoV, MERS-CoV, and SARS-CoV-2 are fatal for humans. It is well established that CypA is essential for the replication of various coronaviruses such as SARS-CoV, CoV-229E, CoV-NL63, and FCoV. Additionally, CsA and its derivatives (ALV, NIM811, etc.) have obvious inhibitory effects on a variety of coronaviruses. These results suggest that CypA is a potential antiviral target and the existing drug CsA might be used as an anti-coronavirus drug. At the end of 2019, SARS-CoV-2 raged in China, which seriously theatern human health and causes huge economic lases. In view of this, we describe the effects of CypA on the replication of coronaviruses and the antiviral activities of its inhibitors, which will provide the scientific basis and ideas for the development of antiviral drugs for SARS-CoV-2.
Antiviral Agents
;
pharmacology
;
therapeutic use
;
Betacoronavirus
;
drug effects
;
growth & development
;
Coronavirus
;
drug effects
;
growth & development
;
Coronavirus Infections
;
drug therapy
;
epidemiology
;
virology
;
Cyclophilin A
;
antagonists & inhibitors
;
Cyclosporine
;
chemistry
;
pharmacology
;
therapeutic use
;
Humans
;
Pandemics
;
Pneumonia, Viral
;
drug therapy
;
epidemiology
;
virology
;
SARS Virus
;
drug effects
;
growth & development
;
Virus Replication
;
drug effects
3.Strategies for vaccine development of COVID-19.
Limin YANG ; Deyu TIAN ; Wenjun LIU
Chinese Journal of Biotechnology 2020;36(4):593-604
An epidemic of acute respiratory syndrome in humans, which appeared in Wuhan, China in December 2019, was caused by a novel coronavirus (SARS-CoV-2). This disease was named as "Coronavirus Disease 2019" (COVID-19). SARS-CoV-2 was first identified as an etiological pathogen of COVID-19, belonging to the species of severe acute respiratory syndrome-related coronaviruses (SARSr-CoV). The speed of both the geographical transmission and the sudden increase in numbers of cases is much faster than SARS and Middle East respiratory syndrome (MERS). COVID-19 is the first global pandemic caused by a coronavirus, which outbreaks in 211 countries/territories/areas. The vaccine against COVID-19, regarded as an effective prophylactic strategy for control and prevention, is being developed in about 90 institutions worldwide. The experiences and lessons encountered in the previous SARS and MERS vaccine research can be used for reference in the development of COVID-19 vaccine. The present paper hopes to provide some insights for COVID-19 vaccines researchers.
Betacoronavirus
;
immunology
;
Biomedical Research
;
Coronavirus Infections
;
epidemiology
;
immunology
;
prevention & control
;
virology
;
Humans
;
Internationality
;
Middle East Respiratory Syndrome Coronavirus
;
immunology
;
Pandemics
;
prevention & control
;
Pneumonia, Viral
;
epidemiology
;
immunology
;
prevention & control
;
virology
;
SARS Virus
;
immunology
;
Severe Acute Respiratory Syndrome
;
immunology
;
Viral Vaccines
;
immunology
5.Expert consensus on the management strategy of patients with hereditary ataxia during prevention and control of novel coronavirus pneumonia epidemic.
SPECIALIZED COMMITTEE OF NEUROGENETICS NEUROPHYSICIAN BRANCH OF CHINESE MEDICAL DOCTOR ASSOCIATION ; Hong JIANG ; Beisha TANG
Chinese Journal of Medical Genetics 2020;37(4):359-366
Since December 2019, a series of highly infectious cases of unexplained pneumonia have been discovered in Wuhan, Hubei Province, which have been confirmed as '2019 corona virus disease' caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 virus can invade many human systems including the lungs. Patients with central nervous system involvement may show a series of neurological symptoms, which is easy to be misdiagnosed and neglected, thereby increasing the risk of SARS-CoV-2 transmission. Hereditary ataxia is a large group of neurodegenerative diseases with great clinical and genetic heterogeneity and high mortality and disability. In view of the seriousness of the COVID-19 epidemic, a series of prevention and control measures adopted by the government have restricted the follow-up, diagnosis and treatment of patients by the hospitals, which has a great impact on their mental and physical health. In order to standardize the management of patients during the prevention and control of COVID-19 epidemic, the Specialized Committee of Neurogenetics of the Neurophysician Branch of Chinese Medical Doctor Association has formulated this consensus, with an aim to help patients to overcome the difficulties and pass the epidemic prevention period safely.
Betacoronavirus
;
China
;
epidemiology
;
Consensus
;
Coronavirus Infections
;
complications
;
epidemiology
;
Epidemics
;
Health Status
;
Humans
;
Mental Health
;
Nervous System Diseases
;
virology
;
Pandemics
;
Pneumonia, Viral
;
complications
;
epidemiology
;
Spinocerebellar Degenerations
;
complications
;
diagnosis
;
prevention & control
;
therapy
6.Management of COVID-19: the Zhejiang experience.
Kaijin XU ; Hongliu CAI ; Yihong SHEN ; Qin NI ; Yu CHEN ; Shaohua HU ; Jianping LI ; Huafen WANG ; Liang YU ; He HUANG ; Yunqing QIU ; Guoqing WEI ; Qiang FANG ; Jianying ZHOU ; Jifang SHENG ; Tingbo LIANG ; Lanjuan LI
Journal of Zhejiang University. Medical sciences 2020;49(2):147-157
The current epidemic situation of coronavirus disease 2019 (COVID-19) still remained severe. As the National Clinical Research Center for Infectious Diseases, the First Affiliated Hospital of Zhejiang University School of Medicine is the primary medical care center for COVID-19 in Zhejiang province. Based on the present expert consensus carried out by National Health Commission and National Administration of Traditional Chinese Medicine, our team summarized and established an effective treatment strategy centered on "Four-Anti and Two-Balance" for clinical practice. The "Four-Anti and Two-Balance" strategy included antivirus, anti-shock, anti-hyoxemia, anti-secondary infection, and maintaining of water, electrolyte and acid base balance and microecological balance. Meanwhile, integrated multidisciplinary personalized treatment was recommended to improve therapeutic effect. The importance of early viralogical detection, dynamic monitoring of inflammatory indexes and chest radiograph was emphasized in clinical decision-making. Sputum was observed with the highest positive rate of RT-PCR results. Viral nucleic acids could be detected in 10%patients' blood samples at acute period and 50%of patients had positive RT-PCR results in their feces. We also isolated alive viral strains from feces, indicating potential infectiousness of feces.Dynamic cytokine detection was necessary to timely identifying cytokine storms and application of artificial liver blood purification system. The "Four-Anti and Two-Balance" strategy effectively increased cure rate and reduced mortality. Early antiviral treatment could alleviate disease severity and prevent illness progression, and we found lopinavir/ritonavir combined with abidol showed antiviral effects in COVID-19. Shock and hypoxemia were usually caused by cytokine storms. The artificial liver blood purification system could rapidly remove inflammatory mediators and block cytokine storm.Moreover, it also favored the balance of fluid, electrolyte and acid-base and thus improved treatment efficacy in critical illness. For cases of severe illness, early and also short period of moderate glucocorticoid was supported. Patients with oxygenation index below 200 mmHg should be transferred to intensive medical center. Conservative oxygen therapy was preferred and noninvasive ventilation was not recommended. Patients with mechanical ventilation should be strictly supervised with cluster ventilator-associated pneumonia prevention strategies. Antimicrobial prophylaxis was not recommended except for patients with long course of disease, repeated fever and elevated procalcitonin (PCT), meanwhile secondary fungal infection should be concerned.Some patients with COVID-19 showed intestinal microbial dysbiosis with decreased probiotics such as and , so nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation. Anxiety and fear were common in patients with COVID-19. Therefore,we established dynamic assessment and warning for psychological crisis. We also integrated Chinese medicine in treatment to promote disease rehabilitation through classification methods of traditional Chinese medicine. We optimized nursing process for severe patients to promote their rehabilitation. It remained unclear about viral clearance pattern after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Therefore, two weeks' quarantine for discharged patients was required and a regular following up was also needed.The Zhejiang experience and suggestions have been implemented in our center and achieved good results. However, since COVID-19 was a newly emerging disease, more work was warranted to improve strategies of prevention, diagnosis and treatment for COVID-19.
Betacoronavirus
;
isolation & purification
;
China
;
epidemiology
;
Coronavirus Infections
;
diagnosis
;
epidemiology
;
therapy
;
virology
;
Disease Management
;
Early Diagnosis
;
Feces
;
virology
;
Humans
;
Pandemics
;
Pneumonia, Viral
;
diagnosis
;
epidemiology
;
therapy
;
virology
;
Sputum
;
virology
7.Coronavirus Disease 2019 Influenza A in Children: An Observational Control Study in China.
Yang ZHAO ; De Lin SUN ; Heather C BOUCHARD ; Xin Xin ZHANG ; Gang WAN ; Yi Wei HAO ; Shu Xin HE ; Yu Yong JIANG ; Lin PANG
Biomedical and Environmental Sciences 2020;33(8):614-619
This study aimed to understand the differences in clinical, epidemiological, and laboratory features between the new coronavirus disease 2019 (COVID-2019) and influenza A in children. Data of 23 hospitalized children with COVID-19 (9 boys, 5.7 ± 3.8 years old) were compared with age- and sex-matched 69 hospitalized and 69 outpatient children with influenza A from a hospital in China. The participants' epidemiological history, family cluster, clinical manifestations, and blood test results were assessed. Compared with either inpatients or outpatients with influenza A, children with COVID-19 showed significantly more frequent family infections and higher ratio of low fever (< 37.3 °C), but shorter cough and fever duration, lower body temperature, and lower rates of cough, fever, high fever (> 39 °C), nasal congestion, rhinorrhea, sore throat, vomiting, myalgia or arthralgia, and febrile seizures. They also showed higher counts of lymphocytes, T lymphocyte CD8, and platelets and levels of cholinesterase, aspartate aminotransferase, lactate dehydrogenase, and lactic acid, but lower serum amyloid, C-reactive protein, and fibrinogen levels and erythrocyte sedimentation rate, and shorter prothrombin time. The level of alanine aminotransferase in children with COVID-19 is lower than that in inpatients but higher than that in outpatients with influenza A. Pediatric COVID-19 is associated with more frequent family infection, milder symptoms, and milder immune responses relative to pediatric influenza A.
Betacoronavirus
;
physiology
;
Case-Control Studies
;
Child
;
Coronavirus Infections
;
blood
;
epidemiology
;
immunology
;
virology
;
Female
;
Humans
;
Influenza, Human
;
blood
;
epidemiology
;
immunology
;
Male
;
Pandemics
;
Pneumonia, Viral
;
blood
;
epidemiology
;
immunology
;
virology
9.Gastrointestinal involvement of COVID-19 and potential faecal transmission of SARS-CoV-2.
Min SONG ; Zong-Lin LI ; Ye-Jiang ZHOU ; Gang TIAN ; Ting YE ; Zhang-Rui ZENG ; Jian DENG ; Hong WAN ; Qing LI ; Jin-Bo LIU
Journal of Zhejiang University. Science. B 2020;21(9):749-751
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was found initially in Wuhan, China in early December 2019. The pandemic has spread to 216 countries and regions, infecting more than 23310 000 people and causing over 800 000 deaths globally by Aug. 24, 2020, according to World Health Organization (https://www.who.int/emergencies/diseases/ novel-coronavirus-2019). Fever, cough, and dyspnea are the three common symptoms of the condition, whereas the conventional transmission route for SARS-CoV-2 is through droplets entering the respiratory tract. To date, infection control measures for COVID-19 have been focusing on the involvement of the respiratory system. However, ignoring potential faecal transmission and the gastrointestinal involvement of SARS-CoV-2 may result in mistakes in attempts to control the pandemic.
Betacoronavirus/isolation & purification*
;
COVID-19
;
China/epidemiology*
;
Coronavirus Infections/virology*
;
Environmental Microbiology
;
Feces/virology*
;
Gastrointestinal Diseases/virology*
;
Humans
;
Models, Biological
;
Pandemics
;
Pneumonia, Viral/virology*
;
RNA, Viral/genetics*
;
SARS-CoV-2
;
Virus Shedding
10.Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea.
Myoung Don OH ; Wan Beom PARK ; Sang Won PARK ; Pyoeng Gyun CHOE ; Ji Hwan BANG ; Kyoung Ho SONG ; Eu Suk KIM ; Hong Bin KIM ; Nam Joong KIM
The Korean Journal of Internal Medicine 2018;33(2):233-246
Middle East Respiratory Syndrome coronavirus (MERS-CoV) was first isolated from a patient with severe pneumonia in 2012. The 2015 Korea outbreak of MERSCoV involved 186 cases, including 38 fatalities. A total of 83% of transmission events were due to five superspreaders, and 44% of the 186 MERS cases were the patients who had been exposed in nosocomial transmission at 16 hospitals. The epidemic lasted for 2 months and the government quarantined 16,993 individuals for 14 days to control the outbreak. This outbreak provides a unique opportunity to fill the gap in our knowledge of MERS-CoV infection. Therefore, in this paper, we review the literature on epidemiology, virology, clinical features, and prevention of MERS-CoV, which were acquired from the 2015 Korea outbreak of MERS-CoV.
Coronavirus
;
Coronavirus Infections*
;
Disease Outbreaks
;
Epidemiology
;
Humans
;
Korea
;
Middle East Respiratory Syndrome Coronavirus
;
Middle East*
;
Pneumonia
;
Republic of Korea*
;
Virology

Result Analysis
Print
Save
E-mail